Dimensional Fund Advisors LP Sells 1,036 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Dimensional Fund Advisors LP trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 61,665 shares of the company’s stock after selling 1,036 shares during the quarter. Dimensional Fund Advisors LP’s holdings in BridgeBio Pharma were worth $1,692,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its stake in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after buying an additional 19,978 shares in the last quarter. Teacher Retirement System of Texas raised its position in BridgeBio Pharma by 28.6% in the 4th quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock worth $994,000 after purchasing an additional 8,048 shares during the last quarter. Vanguard Group Inc. raised its position in BridgeBio Pharma by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after purchasing an additional 879,059 shares during the last quarter. Legal & General Group Plc boosted its holdings in BridgeBio Pharma by 2.8% in the fourth quarter. Legal & General Group Plc now owns 134,038 shares of the company’s stock valued at $3,678,000 after acquiring an additional 3,706 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of BridgeBio Pharma by 9.6% during the 4th quarter. American Century Companies Inc. now owns 1,015,728 shares of the company’s stock worth $27,872,000 after buying an additional 88,882 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 31,543 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02. Following the completion of the sale, the chief executive officer now owns 211,718 shares of the company’s stock, valued at $7,651,488.52. This trade represents a 12.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total value of $197,760,000.00. Following the sale, the insider now directly owns 19,260,971 shares in the company, valued at approximately $634,841,604.16. The trade was a 23.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,410,217 shares of company stock valued at $417,634,332. Insiders own 18.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BBIO shares. HC Wainwright boosted their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, April 15th. Scotiabank increased their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the stock a “sector outperform” rating in a report on Wednesday, April 30th. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday, March 31st. They issued a “buy” rating and a $50.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. boosted their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.09.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $33.66 on Thursday. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of -11.81 and a beta of 1.15. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.54. The business’s fifty day moving average is $34.35 and its 200-day moving average is $31.41.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. During the same quarter in the prior year, the business earned ($0.20) EPS. BridgeBio Pharma’s revenue for the quarter was down 44.8% compared to the same quarter last year. Research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.